Design and implementation of electronic identity application for gene-directed personalized medicine
10.12092/j.issn.1009-2501.2022.03.005
- Author:
Yuanyuan SUN
1
;
Kunhong DENG
1
;
Siyi WANG
1
;
Yun KUANG
1
;
Chan ZOU
1
;
Chengxian GUO
1
;
Guoping YANG
1
;
Qingnan HE
2
;
Siyi WANG
3
;
Helin LIU
4
Author Information
1. Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University
2. The Third Xiangya Hospital of Central South University
3. XiangYa School of Pharmaceutical Sciences, Central South University
4. See Data Technology Corporation
- Publication Type:Journal Article
- Keywords:
APP;
GeneFace;
Personalized medicine;
Pharmacogenomics
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(3):274-280
- CountryChina
- Language:Chinese
-
Abstract:
AIM: In order to bridge the gap between pharmacogenomic research and its clinical application, we propose the concept of genetic electronic identity, named "GeneFace", and developed an electronic information system which integrated "drug-gene" interactions and recommendations for personalized medicine. METHODS: Based on the self-developed Precision Medicine knowledgebase, which concludes drug directions, guidelines or important literatures with high level of evidence, we developed GeneFace with Java-based open-resource application framework Spring Boot, further developed a mobile App with cross-platform framework Uni-APP. RESULTS: The App includes six modules: genetic testing appointment, genetic knowledge introduction, individualized medication advice, medication records, Geneface interpretation, and Precision Medicine knowledgebase. By detecting the genotype of more than 300 gene loci upon first use, users import the results to form a personal "drug-gene identity card". Then scan or enter the drug name in "GeneFace", the App would automatically give corresponding medication recommendations, including: risks for possible adverse drug reactions, risks for reducing the efficacy or even ineffectiveness, and possibility for dose adjustment, etc., which increase the safety of clinical drug use. People can obtain pharmacogenomics knowledge and basic drug information in the "GeneFace" app. CONCLUSION: Development as a digital therapeutic product, the expanded application of GeneFace can rapidly promote clinical applications of basic pharmacogenomics research and significantly improve drug use safety, which creating a new model for accelerating the clinical application of personalized medicine.
